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Abstract
Berberine is used in traditional Chinese medicine for 
the treatment of congestive heart failure, hypertension, 
diabetes, and dyslipidaemia and has a good safety pro-
file. We report a case of a 53-year-old sportsman re-
ferred to our hospital for the onset of fatigue and dys-
pnoea upon exertion after he started berberine to treat 
hypercholesterolaemia. An electrocardiogram showed 
sinus bradycardia (45 bpm), first-degree atrioventricu-
lar block, and competitive junctional rhythm. An ergo-
metric stress test showed slightly reduced chronotropic 
competence and the presence of runs of competitive 
junctional rhythm, atrial tachycardia, and sinus pauses 
in the recovery. After 10 d of wash-out from berber-
ine, the patient experienced a complete resolution of 
symptoms, and an ergometric stress test showed good 
chronotropic competence. An electrocardiogram Holter 
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showed a latent hypervagotonic state. This is the first 
case report that shows that berberine could present 
certain side effects in hypervagotonic people, even in 
the absence of a situation that could cause drug accu-
mulation. Therefore, berberine’s use should be carefully 
weighed in hypervagotonic people due to the drug’s 
bradycardic and antiarrhythmic properties, which could 
became proarrhythmic, exposing patients to potential 
health risks.
© 2013 Baishideng. All rights reserved.
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Core tip: Berberine is widely used in traditional Chinese 
medicine for the treatment of congestive heart failure, 
hypertension, diabetes, and dyslipidaemia. We report 
a case of marked symptomatic sinus bradycardia with 
competitive junctional rhythm caused by berberine, 
showing that berberine, due to its antiarrhythmic prop-
erties, can cause the onset of bradyarrhythmia. In this 
case report, we focus on the possible side effects of so-
called natural medicine based on holistic, home, and 
herbal remedies, which is considered to be safe only 
because the treatment is natural. However, under cer-
tain conditions, natural medicine can lead to potential 
health risks in patients.
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INTRODUCTION
Berberine is an alkaloid from Hydrastis canadensis L., the 
Chinese herb Huang Lian, and many other plants. Berber-
ine is widely used in traditional Chinese medicine for the 
treatment of  congestive heart failure[1-3], hypertension[3], 
diabetes, and dyslipidaemia[4-5]. Berberine has multiple 
cardiovascular effects, including negative chronotropic, 
antiarrhythmic and vasodilatory properties[1,2] and an anti-
inflammatory effect[6]. Several cardiovascular effects of  
berberine are attributed to the blockade of  K+ channels 
[delayed rectifier and K(ATP)], the stimulation of  Na+-
Ca(2+) exchangers[2,7], and the activation of  cardiac M2 
muscarinic cholinergic receptors[8]. 
Berberine has been tested in acute coronary syndrome 
patients following percutaneous coronary intervention 
(PCI)[6], in congestive heart failure secondary to ischemic 
or idiopathic dilated cardiomyopathy[3], in menopausal 
women[9], in elderly hypercholesterolaemic patients[10], and 
in patients with metabolic syndrome[11], offering various 
therapeutic strategies without evidence of  side effects.
CASE REPORT
We report a brief  case that shows that berberine could 
cause side effects under specific conditions. 
A 53-year-old man was referred to the emergency 
room of  our hospital after the onset of  fatigue and dys-
pnoea upon exertion, with evidence of  bradycardia. He 
was overweight and hyperlipidaemic and used to swim 
three times per week. His medical history was unremark-
able, except that he had started berberine 6 d before to 
treat hypercholesterolaemia. Upon physical examina-
tion, the patient presented a normal blood pressure and 
oxygen saturation but an irregular heart rate of  50 bpm. 
He did not present signs of  heart failure, and cardiac, 
pulmonary, and vascular examinations were normal. The 
electrocardiogram (ECG) showed sinus bradycardia with 
a heart rate of  45 bpm, first-degree atrioventricular block 
(PR interval of  280 ms), and a competitive junctional 
rhythm at 55 bpm (Figure 1). Both blood analysis and 
echocardiography did not show any justification for the 
marked bradycardia. An overdose of  berberine was ruled 
out because the patient consumed the correct daily dose. 
Because berberine excretion is hepatobiliary[12], the pres-
ence of  any predisposing factor for reduced excretion, 
such as hepatic or biliary disease, was examined and ruled 
out.
Given the bradycardic and antiarrhythmic properties 
of  berberine, we decided to discontinue the drug, and 
based on the presence of  dyspnoea upon exertion, an 
ergometric stress test was performed to evaluate chrono-
tropic competence. A 24-h wash-out from berberine was 
sufficient before the test, as berberine’s half-life is less 
than 30 min[12]. The ergometric stress test showed slightly 
reduced chronotropic competence, with an increase in 
the heart rate from 45 bpm to 127 bpm, equivalent to 
76% of  the maximal prediction. The test also showed a 
reduction in the atrioventricular conduction delay, with a 
PR that reached 180 ms for a heart rate of  127 bpm. The 
patient presented a good functional class (the test was 
stopped at the second minute of  the step second Bruce 
protocol, METs 13.5). The recovery was characterised by 
the presence of  runs of  competitive junctional rhythm; 
premature supraventricular beats that were occasion-
ally aberrant, sporadically starting brief  runs of  atrial 
tachycardia (Figure 2); and a sinus pause with an RR of  a 
maximum of  1.7 s (Figure 3A). Most likely, the patient’s 
symptoms were not closely related to bradycardia at rest 
but rather to the loss of  AV synchronisation during the 
junctional rhythm and to the reduction in chronotropic 
competence during stress.
Over the following days, the patient experienced a 
complete resolution of  symptoms and performed nor-
mal life activities and his usual sport activity (swimming) 
without experiencing dyspnoea or fatigue. After 10 d of  
wash-out from berberine, he underwent a new ergomet-
ric stress test and an ECG Holter. The ergometric stress 
test was normal. The ECG at rest was characterised by 
the presence of  sinus bradycardia with a heart rate of  43 
bpm and first-degree atrioventricular block (PR at rest of  
280 ms), as presented several days before. However, the 
test presented better chronotropic competence. The test 
was maximal (86% of  the predicted heart rate), despite 
the patient having reached the same workload as in the 
first test. The presence of  first-degree atrioventricular 
block was consistent with a PR interval normalised at a 
high rate.
During the ECG-Holter monitoring, we observed a 
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Figure 1  Competitive junctional rhythm.
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Figure 2  Junctional beats, premature supraventricular beats, sometimes 
aberrant starting brief runs of atrial tachycardia.
sight typical of  a hypervagotonic state: bradycardial sinus 
rhythm with normal variation of  the heart rate with a 
circadian cycle and physical activity (FC maximum 104, 
average 56, minimum 40 bpm); several nocturnal runs of  
sinus bradycardia at 30 bpm; and several, especially noc-
turnal sinus pauses, with an RR interval of  2.4 s (Figure 
3B). 
The patient continued to be asymptomatic and to 
practice his normal life and sport activities and treated his 
dyslipidaemia with diet. 
DISCUSSION
This is the first case report that shows that berberine 
could present certain side effects in hypervagotonic peo-
ple, even in the absence of  a situation that could cause 
drug accumulation. Indeed, berberine has been found 
to have a good safety profile[2,3,5,6,9-11] in patients with 
pathological conditions characterised by a hyperadrener-
gic state, such as acute coronary syndrome[13], heart fail-
ure[14,15], diabetes[16], hypertension[17], and menopause[18]. 
In a murine model, it has been proven that berberine 
reduces plasma adrenaline and noradrenaline levels[19]. We 
do not know whether the bradycardic and antiarrhyth-
mic properties of  berberine are vagally mediated by the 
activation of  muscarinic receptors, as shown by Salehi et 
al[8], or are not vagally mediated, as reported by Shaffer[20]. 
However, it is possible that in hypervagotonic people 
with marked sinus bradycardia, berberine’s bradycardic 
effect can induce the onset of  competitive junctional 
rhythm, causing a loss of  atrioventricular synchronisation, 
and can reduce chronotropic competence with the onset 
of  symptoms upon exertion. Therefore, berberine’s use 
should be carefully weighed in hypervagotonic people 
due to the drug’s bradycardic and antiarrhythmic proper-
ties, which could become proarrhythmic, exposing pa-
tients to potential health risks. 
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Figure 3  Sinus pause. A: With an RR of max 1.7 s; B: With an RR 2.4 s.
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